FDA Approves Supplement for HEPZATO by Delcath Systems
The FDA has approved a supplemental application for HEPZATO, containing melphalan hydrochloride.
Published: July 21, 2026
Updated: July 21, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / Chemotherapy
Asset: HEPZATO
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
HEPZATO
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of the supplemental application for HEPZATO is significant as it strengthens Delcath Systems' position in the competitive oncology landscape. This could lead to shifts in market dynamics and necessitates close monitoring of competitive responses and market entry strategies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for further details on the approved indications and market launch timelines.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.